Intensity Therapeutics Inc. (NASDAQ:INTS) Shares Shorted: Short Interest Up 129.4% in October

Intensity Therapeutics Inc. (NASDAQ:INTS) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 87,767 shares, an increase of 129.4% from the September 30th total of 38,253 shares. Approximately 2.9% of the shares of the stock are sold short. Based on an average trading volume of 28,905 shares, the short-interest ratio is presently 3.0 days.

Intensity Therapeutics Price Performance

Shares of INTS opened at $3.40 on Friday. The firm’s 50-day simple moving average is $3.77 and its two-hundred day simple moving average is $5.28. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.00 and a current ratio of 5.00. The stock has a market cap of $11.08 million, a PE ratio of -0.95 and a beta of 2.81. Intensity Therapeutics has a fifty-two week low of $3.00 and a fifty-two week high of $28.75.

Intensity Therapeutics (NASDAQ:INTS) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.24). Analysts anticipate that Intensity Therapeutics will post -2.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. HC Wainwright raised their price objective on Intensity Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Monday, October 19th. Finally, Citigroup restated a “buy” rating on shares of Intensity Therapeutics in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

About Intensity Therapeutics

Intensity Therapeutics, Inc (NASDAQ: INTS) is a clinical-stage biotechnology company developing investigational cancer immunotherapies designed to treat solid tumors. Its approach focuses on injecting therapies directly into tumors to promote tumor-cell destruction and stimulate a broader immune response against cancer.

The company’s lead product candidate, INT230-6, is a proprietary formulation containing the chemotherapy agents cisplatin and vinblastine combined with an amphiphilic delivery agent.